Show simple item record

dc.contributor.authorHicks, S
dc.contributor.authorPohl, K
dc.contributor.authorNeeman, T
dc.contributor.authorMcNamara, H
dc.contributor.authorParsons, K
dc.contributor.authorHe, J-S
dc.contributor.authorAli, S
dc.contributor.authorNazir, S
dc.contributor.authorRowntree, L
dc.contributor.authorNguyen, T
dc.contributor.authorKedzierska, K
dc.contributor.authorDoolan, D
dc.contributor.authorVinueas, C
dc.contributor.authorCook, M
dc.contributor.authorCoatsworth, N
dc.contributor.authorMyles, P
dc.contributor.authorKurth, F
dc.contributor.authorSander, L
dc.contributor.authorMann, G
dc.contributor.authorGruen, R
dc.contributor.authorGeorge, A
dc.contributor.authorGardiner, E
dc.contributor.authorCockburn, I
dc.contributor.authorthe SARS-CoV-2 Testing in Elective Surgery Collaborators
dc.date.accessioned2020-12-09T22:46:59Z
dc.date.available2020-12-09T22:46:59Z
dc.date.issued2020-09-14
dc.identifier.citationHicks, S., Pohl, K., Neeman, T., McNamara, H., Parsons, K., He, J. -S., Ali, S., Nazir, S., Rowntree, L., Nguyen, T., Kedzierska, K., Doolan, D., Vinueas, C., Cook, M., Coatsworth, N., Myles, P., Kurth, F., Sander, L., Mann, G. ,... the SARS-CoV-2 Testing in Elective Surgery Collaborators (2020). A dual antigen ELISA allows the assessment of SARS-CoV-2 antibody seroprevalence in a low transmission setting. https://doi.org/10.1101/2020.09.09.20191031.
dc.identifier.urihttp://hdl.handle.net/11343/253073
dc.description.abstractEstimates of seroprevalence of SARS-CoV-2 antibodies have been hampered by inadequate assay sensitivity and specificity. Using an ELISA-based approach to that combines data about IgG responses to both the Nucleocapsid and Spike-receptor binding domain antigens, we show that near-optimal sensitivity and specificity can be achieved. We used this assay to assess the frequency of virus-specific antibodies in a cohort of elective surgery patients in Australia and estimated seroprevalence in Australia to be 0.28% (0 to 0.72%). These data confirm the low level of transmission of SARS-CoV-2 in Australia before July 2020 and validate the specificity of our assay.
dc.publisherCold Spring Harbor Laboratory
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.titleA dual antigen ELISA allows the assessment of SARS-CoV-2 antibody seroprevalence in a low transmission setting
dc.typeJournal Article
dc.identifier.doi10.1101/2020.09.09.20191031
melbourne.affiliation.departmentClinical Pathology
dc.rights.licenseCC BY-NC-ND
melbourne.elementsid1467353
melbourne.contributor.authorGeorge, Amee
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record